Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Revenue (2020 - 2025)

Cytek Biosciences' Revenue history spans 6 years, with the latest figure at $62.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 8.12% year-over-year to $62.1 million; the TTM value through Dec 2025 reached $201.5 million, up 0.52%, while the annual FY2025 figure was $201.5 million, 0.52% up from the prior year.
  • Revenue reached $62.1 million in Q4 2025 per CTKB's latest filing, up from $52.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $62.1 million in Q4 2025 to a low of -$86.9 million in Q4 2021.
  • Average Revenue over 5 years is $38.1 million, with a median of $45.2 million recorded in 2024.
  • Peak YoY movement for Revenue: plummeted 41.24% in 2021, then skyrocketed 155.64% in 2022.
  • A 5-year view of Revenue shows it stood at -$86.9 million in 2021, then surged by 155.64% to $48.3 million in 2022, then grew by 20.48% to $58.2 million in 2023, then dropped by 1.3% to $57.5 million in 2024, then grew by 8.12% to $62.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Revenue are $62.1 million (Q4 2025), $52.3 million (Q3 2025), and $45.6 million (Q2 2025).